Medtronic’s revenue increases 5% to $31.69bn in FY22
The company’s fourth quarter worldwide revenue declined by 1% on a reported basis to $8.09bn.

The company’s fourth quarter worldwide revenue declined by 1% on a reported basis to $8.09bn.
The deal adds Intersect ENT's PROPEL and SINUVA sinus implant product lines and technology to Medtronic's portfolio.
According to GlobalData's Medical Devices Deal Database, key M&A activities in China increased significantly from 2018 to 2021.
ByThe device stimulates the posterior tibial nerve to transmit electrical impulses that regulate the bladder’s neural activity.
Rockley and Medtronic are to jointly develop wearable devices for proactive and continuous health monitoring.
The shape of the device enables easy access to the patient’s eustachian tube through the nasal opening.
The devices are designed to freeze the cardiac tissue and block unnecessary electrical signals in the heart.
Starting with coronary stents, the volume-based procurement (VBP) of high-value medical consumables has been carried out in China since 2020.
ByThank you for subscribing to Medical Device Network